Establishment Labs (NASDAQ:ESTA) Reaches New 1-Year High – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares hit a new 52-week high on Monday . The company traded as high as $90.50 and last traded at $90.4970, with a volume of 140799 shares traded. The stock had previously closed at $89.25.

Analysts Set New Price Targets

ESTA has been the topic of a number of recent research reports. BTIG Research upped their target price on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Finally, TD Cowen reissued a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Stock Performance

The firm has a market cap of $2.69 billion, a PE ratio of -61.22 and a beta of 1.06. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a 50-day moving average price of $75.84 and a 200 day moving average price of $70.91.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) earnings per share. Research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 292,500 shares of company stock worth $20,591,021. Corporate insiders own 9.99% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

A number of large investors have recently bought and sold shares of the stock. KBC Group NV acquired a new position in shares of Establishment Labs in the 1st quarter valued at $28,000. Quarry LP acquired a new stake in shares of Establishment Labs during the 3rd quarter worth $34,000. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs during the 4th quarter worth $47,000. Osaic Holdings Inc. raised its position in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the period. Finally, MV Capital Management Inc. purchased a new position in shares of Establishment Labs in the 4th quarter worth $146,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.